{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:16:56Z","timestamp":1767925016421,"version":"3.49.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.1093\/neuonc\/noab164","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T11:08:47Z","timestamp":1625915327000},"page":"1627-1628","source":"Crossref","is-referenced-by-count":6,"title":["Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-895X","authenticated-orcid":false,"given":"Vijay","family":"Ramaswamy","sequence":"first","affiliation":[{"name":"Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-5251","authenticated-orcid":false,"given":"Ute","family":"Bartels","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"2","key":"2021100111122568100_CIT0001","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol."},{"issue":"8","key":"2021100111122568100_CIT0002","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cncr.29907","article-title":"Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study","volume":"122","author":"Krishnatry","year":"2016","journal-title":"Cancer."},{"issue":"7","key":"2021100111122568100_CIT0003","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"2021100111122568100_CIT0004","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol."},{"key":"2021100111122568100_CIT0005","article-title":"A phase 2 trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a pediatric brain tumor consortium study","author":"Fangusaro","journal-title":"Neuro Oncol."},{"issue":"1","key":"2021100111122568100_CIT0006","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer."},{"issue":"25","key":"2021100111122568100_CIT0007","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021100111122568100_CIT0008","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell."},{"issue":"2","key":"2021100111122568100_CIT0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas \u2013 a Pediatric Brain Tumor Consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro Oncol."},{"issue":"29","key":"2021100111122568100_CIT0010","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol."},{"issue":"21","key":"2021100111122568100_CIT0011","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children\u2019s Oncology Group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab164\/39584716\/noab164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1627\/40493888\/noab164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1627\/40493888\/noab164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T17:01:02Z","timestamp":1633107662000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/10\/1627\/6319139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,7,12]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab164","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,7,12]]}}}